TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by State Street Corp

State Street Corp grew its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 35.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,094,158 shares of the biopharmaceutical company's stock after purchasing an additional 2,398,015 shares during the quarter. State Street Corp owned 5.84% of TG Therapeutics worth $212,712,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. acquired a new position in shares of TG Therapeutics in the second quarter worth $8,698,000. Bank of New York Mellon Corp lifted its position in shares of TG Therapeutics by 13.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 503,645 shares of the biopharmaceutical company's stock worth $8,960,000 after buying an additional 59,523 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of TG Therapeutics by 1,080.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 18,313 shares of the biopharmaceutical company's stock valued at $326,000 after buying an additional 16,761 shares in the last quarter. Iridian Asset Management LLC CT purchased a new position in shares of TG Therapeutics in the 2nd quarter valued at $700,000. Finally, Burney Co. acquired a new stake in TG Therapeutics during the 2nd quarter worth $801,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX traded down $0.57 during trading on Thursday, reaching $31.08. The company had a trading volume of 694,683 shares, compared to its average volume of 3,606,251. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a twelve month low of $12.84 and a twelve month high of $36.84. The stock has a 50-day moving average price of $28.20 and a two-hundred day moving average price of $23.19. The stock has a market capitalization of $4.84 billion, a PE ratio of -316.47 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same period in the previous year, the firm posted $0.73 EPS. The company's revenue for the quarter was down 49.4% compared to the same quarter last year. As a group, sell-side analysts predict that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Insider Activity

In other news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 10.50% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. StockNews.com cut shares of TG Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, December 6th. The Goldman Sachs Group raised their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. upped their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. HC Wainwright lifted their price target on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Finally, TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.